论文部分内容阅读
目的探讨替尼泊甙(VM-26)为主的化疗方案相伴放疗治疗小细胞肺癌的临床疗效。方法53例小细胞肺癌中,48例选用VM-26+顺铂(DDP)方案,VM-26每天60mg/m2,DDP每天25mg/m2,连用3天为一个疗程;另5例用卡铂取代DDP,500mg静脉滴注,1天完成。除第1个与第2个疗程化疗间隔40天左右外,以后每4周重复1个疗程,共5个疗程。在第1个疗程化疗后1~4天内开始放射治疗。对局限期和广泛期患者分别照射不同的剂量和部位。结果局限期患者近期疗效为97.8%[完全缓解(CR)为53.3%,部分缓解(PR)为44.8%],1年和2年生存率分别为77.1%(27/35)和44%(11/25),中位生存期大于18个月。广泛期患者近期疗效为75%(CR25%),一年生存率为37.5%(3/8),中位生存期大于11个月。结论以VM-26为主的化疗方案相伴放疗是治疗小细胞肺癌的有效方案,可提高肿瘤的局部控制率。
Objective To investigate the clinical efficacy of the chemotherapy regimen based on teniposide (VM-26) combined with radiotherapy for small cell lung cancer. Methods Among 53 cases of small cell lung cancer, 48 cases were treated with VM-26+cisplatin (DDP), VM-26 was given at 60mg/m2 daily, DDP was given at 25mg/m2 daily for 3 days as a course of treatment. The other 5 patients were treated with carboplatin instead of DDP. , 500mg intravenous infusion, completed in 1 day. In addition to the 40-day interval between the first and second courses of chemotherapy, a course of treatment is repeated every 4 weeks for a total of 5 courses. Radiotherapy was started within 1 to 4 days after the first course of chemotherapy. Patients with limited and extensive periods were exposed to different doses and sites. Results The short-term efficacy of the patients in the phase-limited period was 97.8% [53.3% for complete remission (CR), 44.8% for partial remission (PR)], and the 1-year and 2-year survival rates were 77.1%, respectively (27 / 35) and 44% (11/25), with a median survival of more than 18 months. The short-term efficacy of extensive patients was 75% (CR25%), the one-year survival rate was 37.5% (3/8), and the median survival was greater than 11 months. Conclusion VM-26-based chemotherapy combined with radiotherapy is an effective treatment for small cell lung cancer, which can increase the local control rate of tumors.